-
Innovative Strategies for Antibody Lead Discovery and Optimization
Ernst Weber, Bayer AG, Leverkusen Multiple parameters of an antibody have to be met in order to qualify an initial screening hit as suitable candidate for development and to finally become a drug. They include i) functional parameters like high...
https://www.elrig.de/index.php/elrig-foren/elrig-forum-2020/forum2020-abstracts/296-weber-abs20 -
Development of lead molecules for antibody therapies
André Frenzel, YUMAB GmbH, Braunschweig,Germany Antibody phage display has been used for the discovery of therapeutic antibodies since decades. Although several alternative technologies have been developed in the meantime such as single B-cell cloning...
https://www.elrig.de/index.php/elrig-foren/elrig-forum-2020/forum2020-abstracts/304-frenz-abs20 -
Hit and Lead Generation in Large Molecule Drug Discovery
Dr. Georg Fertig, Roche, Penzberg, Germany Monoclonal antibodies are meanwhile the most target specific drugs on the market. Due to this, the failure during preclinical and early stage development is low compared to small molecules, which makes them...
https://www.elrig.de/index.php/elrig-foren/elrig-forum-2014/forum2014-abstracts/56-roche
Unter der Annahme, dass „antibody“ benötigt wird und „lead“ benötigt wird und „discovery“ benötigt wird, wurden folgende Ergebnisse gefunden:
Ergebnisse 1 - 3 von 3
